NVO
Novo Nordisk A/S
NVO has slightly lower modeled downside risk, despite its lower overall score.
SMCI
Super Micro Computer, Inc.
SMCI has the edge over NVO overall, supported by stronger valuation and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SMCI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Weak | |
| Strong |
SMCI's revenue, profitability and balance sheet are currently strong, but its cash flow is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SMCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.3x | $26.99 | — |
| Current | 5.7x | $26.99 | — |
| Cheap | 13x | $61.50 | +128% |
| Fair | 19x | $88.86 | +229% |
| Expensive | 26x | $125 | +363% |
Historical ranges are pointers, not guarantees.
SMCI has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SMCI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Moderate | |
| Low |
SMCI has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SMCI on earnings, with more consistent year-over-year improvement.
SMCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.22 | +31% |
| Q3 2026 | $4.75 | +274% |
| Q2 2026 | $3.26 | +94% |
| Q1 2026 | $1.91 | +4.4% |
| Q4 2025 | $1.36 | -41% |
| Q3 2025 | $1.27 | -45% |
| Q2 2025 | $1.68 | -13% |
| Q1 2025 | $1.83 | +2.8% |
| Q4 2024 | $2.32 | +81% |
SMCI's earnings per share have jumped to their highest in seven years: $4.75 over the past year, up from $1.27 the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SMCI on profitability, with a higher operating margin.
SMCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.9B | +298% |
| Q2 2026 | $11.1B | +93% |
| Q1 2026 | $10.2B | +123% |
| Q4 2025 | $12.7B | +123% |
| Q3 2025 | $5B | -15% |
| Q2 2025 | $5.8B | +7.5% |
| Q1 2025 | $4.6B | +19% |
| Q4 2024 | $5.7B | +55% |
SMCI has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +6.7 points |
| Q2 2026 | 13% | +9.4 points |
| Q1 2026 | 6.1% | +2.9 points |
| Q4 2025 | 3.7% | -2.8 points |
| Q3 2025 | 3.6% | -5 points |
| Q2 2025 | 4% | -1.4 points |
| Q1 2025 | 3.2% | -6.6 points |
| Q4 2024 | 6.5% | -3.7 points |
SMCI's operating margin was 10% last quarter, up 6.7 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SMCI on cash generation, producing positive trailing cash flow while its opponent burns cash.
SMCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$475.6M | +$474.2M |
| Q2 2026 | $718.7M | -15% |
| Q1 2026 | -$6.7B | -1227% |
| Q4 2025 | -$45.1M | +$222.2M |
| Q3 2025 | -$949.8M | -360% |
| Q2 2025 | $840.9M | +$1.5B |
| Q1 2025 | $594.1M | +$2.2B |
| Q4 2024 | -$267.3M | +$342.5M |
SMCI's free cash flow was −$6.5B over the past year, against $218M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SMCI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SMCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.5% | +52M shares |
| 1 year | +13% | +86.1M shares |
| 3 years | +31% | +178M shares |
| 5 years | +42% | +220M shares |
| Available history | +44% | +229M shares |
SMCI has 749M diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | $12M |
| Q1 2021 | $43.1M |
| Q4 2020 | $46.4M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SMCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | 0.2x | Very low |
SMCI has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SMCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.8 | Neutral |
| Stochastic | 19.1 | Oversold |
SMCI's weekly RSI is 41 (neutral) and its Stochastic is 19 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SMCI PE vs Technology Sector
| Metric | SMCI | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 28x | 80% below |
| PE % | 0 | 35 | 35 pts below |
SMCI has the edge over NVO on valuation relative to its sector.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over SMCI on trend strength, trading above more of its moving averages.
SMCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.3 | 23% below |
| 20 week MA | $34.2 | 21% below |
| 50 week MA | $32.3 | 17% below |
| 100 week MA | $36.9 | 27% below |
| 200 week MA | $39.8 | 32% below |
SMCI is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
SMCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.41 | $3.05 | +27% |
| 2021 | $3.05 | $4.27 | +40% |
| 2022 | $4.27 | $8.22 | +93% |
| 2023 | $8.22 | $28.4 | +246% |
| 2024 | $28.4 | $32.0 | +12% |
| 2025 | $32.0 | $30.6 | -4.2% |
| 2026 YTD | $30.6 | $27.0 | -12% |
SMCI has the edge over NVO on returns for 2026, with the stronger performance.